Clinical relevance of SARS-CoV-2 infection in late pregnancy.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
12 Jul 2021
Historique:
received: 30 01 2021
accepted: 07 07 2021
entrez: 13 7 2021
pubmed: 14 7 2021
medline: 17 7 2021
Statut: epublish

Résumé

Evidence on the outcome of SARS-CoV-2 infection in pregnancy is generally reassuring but yet not definitive. To specifically assess the impact of SARS-CoV-2 infection in late pregnancy, we prospectively recruited 315 consecutive women delivering in a referral hospital located in Lombardy, Italy in the early phase of the epidemic. Restriction of the recruitment to this peculiar historical time period allowed to exclude infections occurring early in pregnancy and to limit the recall bias. All recruited subjects underwent a nasopharyngeal swab to assess the presence of Sars-Cov-2 using Real-time PCR. In addition, two different types of antibodies for the virus were evaluated in peripheral blood, those against the spike proteins S1 and S2 of the envelope and those against the nucleoprotein of the nucleocapsid. Women were considered to have had SARS-CoV-2 infection in pregnancy if at least one of the three assessments was positive. Overall, 28 women had a diagnosis of SARS-CoV-2 infection in pregnancy (8.9%). Women diagnosed with the infection were more likely to report one or more episodes of symptoms suggestive for Covid-19 (n = 11, 39.3%) compared to unaffected women (n = 39, 13.6%). The corresponding OR was 4.11 (95%CI: 1.79-9.44). Symptoms significantly associated with Covid-19 in pregnancy included fever, cough, dyspnea and anosmia. Only one woman necessitated intensive care. Pregnancy outcome in women with and without SARS-CoV-2 infection did not also differ. SARS-CoV-2 infection is asymptomatic in three out of five women in late pregnancy and is rarely severe. In addition, pregnancy outcome may not be markedly affected.

Sections du résumé

BACKGROUND BACKGROUND
Evidence on the outcome of SARS-CoV-2 infection in pregnancy is generally reassuring but yet not definitive.
METHODS METHODS
To specifically assess the impact of SARS-CoV-2 infection in late pregnancy, we prospectively recruited 315 consecutive women delivering in a referral hospital located in Lombardy, Italy in the early phase of the epidemic. Restriction of the recruitment to this peculiar historical time period allowed to exclude infections occurring early in pregnancy and to limit the recall bias. All recruited subjects underwent a nasopharyngeal swab to assess the presence of Sars-Cov-2 using Real-time PCR. In addition, two different types of antibodies for the virus were evaluated in peripheral blood, those against the spike proteins S1 and S2 of the envelope and those against the nucleoprotein of the nucleocapsid. Women were considered to have had SARS-CoV-2 infection in pregnancy if at least one of the three assessments was positive.
RESULTS RESULTS
Overall, 28 women had a diagnosis of SARS-CoV-2 infection in pregnancy (8.9%). Women diagnosed with the infection were more likely to report one or more episodes of symptoms suggestive for Covid-19 (n = 11, 39.3%) compared to unaffected women (n = 39, 13.6%). The corresponding OR was 4.11 (95%CI: 1.79-9.44). Symptoms significantly associated with Covid-19 in pregnancy included fever, cough, dyspnea and anosmia. Only one woman necessitated intensive care. Pregnancy outcome in women with and without SARS-CoV-2 infection did not also differ.
CONCLUSIONS CONCLUSIONS
SARS-CoV-2 infection is asymptomatic in three out of five women in late pregnancy and is rarely severe. In addition, pregnancy outcome may not be markedly affected.

Identifiants

pubmed: 34253173
doi: 10.1186/s12884-021-03985-1
pii: 10.1186/s12884-021-03985-1
pmc: PMC8273567
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

505

Informations de copyright

© 2021. The Author(s).

Références

JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Hum Reprod. 2016 Dec;31(12):2730-2736
pubmed: 27664955
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Lancet. 2020 Aug 22;396(10250):530-531
pubmed: 32771084
Respirology. 2020 Jul;25(7):680-682
pubmed: 32436320
Clin Infect Dis. 2021 Feb 08;:
pubmed: 33556958
JAMA. 2020 Nov 3;324(17):1782-1785
pubmed: 32965467
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
Ann Ostet Ginecol Med Perinat. 1991 Jul-Aug;112(4):203-46
pubmed: 1807187
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
Int J Gynaecol Obstet. 2020 Jul;150(1):124-126
pubmed: 32369613
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ. 2020 Jun 8;369:m2107
pubmed: 32513659
J Perinat Med. 2020 Nov 26;48(9):900-911
pubmed: 33001856
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
N Engl J Med. 2020 Jun 18;382(25):e100
pubmed: 32302077
Nature. 2020 Apr;580(7805):571-572
pubmed: 32313159
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
EClinicalMedicine. 2020 Aug;25:100446
pubmed: 32838230

Auteurs

Marta Ruggiero (M)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy.
Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy.

Edgardo Somigliana (E)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy. dadosomigliana@yahoo.it.
Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy. dadosomigliana@yahoo.it.

Beatrice Tassis (B)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy.

Letizia Li Piani (L)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy.
Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy.

Sara Uceda Renteria (S)

Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Milan, Italy.

Giussy Barbara (G)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy.

Giovanna Lunghi (G)

Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Milan, Italy.

Carlo Pietrasanta (C)

Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy.
Neonatal Intensive Care Unit (NICU), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Milan, Italy.

Enrico Ferrazzi (E)

Department of Woman, New-Born and Child, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Mangiagalli Centre, Via M. Fanti, 6, 20122, Milan, Italy.
Department of Clinical Sciences and Community Health, Università Degli Studi Di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH